Comparing Belite Bio (BLTE) & The Competition

Belite Bio (NASDAQ:BLTE) is one of 986 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Belite Bio to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, valuation, risk, dividends and earnings.

Volatility & Risk

Belite Bio has a beta of -1.62, meaning that its stock price is 262% less volatile than the S&P 500. Comparatively, Belite Bio’s peers have a beta of 0.85, meaning that their average stock price is 15% less volatile than the S&P 500.

Earnings and Valuation

This table compares Belite Bio and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Belite Bio	N/A	-$31.63 million	-26.96
Belite Bio Competitors	$1.60 billion	$143.27 million	-4.34

Belite Bio’s peers have higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Belite Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0	0	7	0	3.00
Belite Bio Competitors	6211	18346	43834	886	2.57

Belite Bio currently has a consensus target price of $44.83, indicating a potential upside of 34.11%. As a group, “Pharmaceutical preparations” companies have a potential upside of 88.08%. Given Belite Bio’s peers higher possible upside, analysts clearly believe Belite Bio has less favorable growth aspects than its peers.

Insider and Institutional Ownership

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Belite Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-54.05%	-50.06%
Belite Bio Competitors	-2,086.28%	-226.73%	-28.61%

Summary

Belite Bio peers beat Belite Bio on 8 of the 12 factors compared.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.